57 related articles for article (PubMed ID: 25190507)
41. Overexpression of serine threonine tyrosine kinase 1/novel oncogene with kinase domain mRNA in patients with acute leukemia.
Kondoh T; Kobayashi D; Tsuji N; Kuribayashi K; Watanabe N
Exp Hematol; 2009 Jul; 37(7):824-30. PubMed ID: 19409952
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic relevance of overexpressed serine threonine tyrosine kinase/novel oncogene with kinase domain (STYK1/ NOK) mRNA in colorectal cancer.
Orang AV; Safaralizadeh R; Hosseinpour Feizi MA; Somi MH
Asian Pac J Cancer Prev; 2014; 15(16):6685-9. PubMed ID: 25169509
[TBL] [Abstract][Full Text] [Related]
43. Knockdown of Serine Threonine Tyrosine Kinase 1 (STYK1) Inhibits the Migration and Tumorigenesis in Glioma Cells.
Zhou J; Wang F; Liu B; Yang L; Wang X; Liu Y
Oncol Res; 2017 Jul; 25(6):931-937. PubMed ID: 27983928
[TBL] [Abstract][Full Text] [Related]
44. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
45. Significance of serine threonine tyrosine kinase 1 as a drug resistance factor and therapeutic predictor in acute leukemia.
Nirasawa S; Kobayashi D; Kondoh T; Kuribayashi K; Tanaka M; Yanagihara N; Watanabe N
Int J Oncol; 2014 Nov; 45(5):1867-74. PubMed ID: 25190507
[TBL] [Abstract][Full Text] [Related]
46. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
47. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
48. Insights into molecular pathways for targeted therapeutics in acute leukemia.
Stavropoulou V; Brault L; Schwaller J
Swiss Med Wkly; 2010; 140():w13068. PubMed ID: 20853191
[TBL] [Abstract][Full Text] [Related]
49.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
50.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
51.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
52.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
